We recently reported the expression of human papillomavirus type 18 (HPV-18) E6 protein in bacteria and the production of anti-E6 polyclonal antibodies. This work has now been extended with the production of a panel ofmonoclonal antibodies against the HPV-18 E6 protein. These antibodies demonstrate that there is little antigenic conservation in the E6 protein between HPV-16 and HPV-18, with only one antibody recognizing a cross-reactive epitope. We have used both the monoclonal and the polyclonal antibodies to look for E6 expression in a number of HPV DNA-containing cell lines. These reagents specifically detected a 16.5K tool. wt. polypeptide in cells derived from a human cervical carcinoma.
INTRODUCTION
Human papillomaviruses (HPVs) induce epithelial or fibroepithelial proliferations of skin or mucosa (zur Hausen, 1977) . Infection with specific HPV types correlates with specific diseases such as common warts, epidermodysplasia verruciformis and genital warts (Pfister, 1984) . In addition infection with some HPV types has been closely linked with specific human cancers. In particular, HPV-16 and HPV-18 DNAs have been found in a large proportion of malignant lesions of the cervix (Durst et al., 1983 ; Boshart et al., 1984) , as well as in a number of cell lines derived from human cervical carcinomas. In some cases these DNAs are transcribed (Schwarz et al., 1985; Yee et al., 1985) and HPV-coded proteins are expressed (Smotkin & Wettstein, 1986) .
Until recently, bovine papillomavirus (BPV-1) served as the prototype for the study of the molecular biology and transforming genes of papillomaviruses. These studies have shown that the BPV-1 E6 open reading frame (ORF) is necessary for efficient transformation of mouse C 127 cells (Schiller et aL, 1984; Yang et al., 1985; Androphy eta[., 1985) , and in one case using a BPV-1 E6-specific antiserum, E6 protein has been demonstrated (Androphy et al., 1985) . More recently, the direct transforming ability of HPV-16 D NA has been demonstrated in vitro, both in the form of molecularly cloned HPV-16 DNA (Yasumoto et al., 1986) and also HPV-16 DNA derived directly from a cervical tumour biopsy (Tsunokawa et al., 1986) . In both cases the HPV-16 DNA was transcribed.
We recently reported the synthesis of HPV-18 E6 polypeptide in bacteria (Matlashewski et al., 1986a) . The present paper reports the isolation of a panel of monoclonal antibodies to the HPV-18 E6 polypeptide, and their use in the immunological analysis of the E6 protein derived from different HPVs. The use of these reagents for analysis of E6 expression in a variety of HPV DNA-containing transformed cells is also described.
METHODS
Cells. C33-I (Auersperg, 1964) , HeLa (Puck et al., 1958) , CaSki (Patillo, 1977) and SiHa (Friedl et al., 1979) cells were grown in Dulbecco's modified Eagle's (DME) medium supplemented with 10~ foetal calf serum.
Preparation ofmonoclonal antibodies. BALB/c mice were inoculated twice subcutaneously with 1 to 2 gg of gelpurified HPV-18 E6-fl galactosidase fusion protein in incomplete Freund's adjuvant. Three days prior to cell fusion, mice were given an intravenous boost with a further 2 gg The cell fusion technique was then as described previously (Banks et al., 1983) .
Immunoblotting. For analysis of E6 protein synthesized in bacteria, isopropyl-fl-thiogalactoside (100 gg/ml) or nalidixic acid (40 pg/ml)-induced cells were resuspended in 3 ~ SDS, 1-6 M-urea, 33 mM-2-mercaptoethanol, boiled and the extracts analysed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
Immunoblotting and subsequent detection were as described previously (Banks et al., 1986) . Plasmid construction for bacterial synthesis of E6 protein. The plasmid constructions for the generation of the HPV-18 E6-fl-galactosidase fusion protein (pUR-18 E6) and of the HPV-18 E6 15.8K protein (pAS-18 E6) have been described previously (Matlashewski et al., 1986a) . The pAS construction gives the E6 protein without any significant additional sequence (Rosenberg et al., 1983) . Plasmid construction for HPV-16 E6 17K protein (pAS-16E6) was as follows. From HPV-16 sequence information (Seedorf et al., 1985) we calculated that a DdeI fragment from nucleotides 24 to 654 contains the entire HPV-16 E60RF plus additional 5' and 3' terminal noncoding regions. This DdeI fragment was treated briefly with Bal31 exonuclease which resulted in a 551 bp fragment from nucleotides 68 to 619. This would code for all the HPV-16 E6 amino acids through to the C terminus, plus five additional amino acids preceding the putative N terminus of E6. BamHI linkers were ligated onto this fragment which was then inserted into BamHI-cut pAS-1 vector (Rosenberg et al., 1983) . The ligation mixture was used to transform Escherichia cob AR 120 which contains the 2 CI gene. Ampicillin-resistant clones were grown at 37 °C to an A550 of 1 and then in the presence of 40 gg/ml nalidixic acid for an additional 4 h at 37°C. Cells were then pelleted and resuspended in 3 ~ SDS, 1.6 M-urea, 33 mM-2-mercaptoethanol and the proteins were analysed by SDS-PAGE and immunoblotting.
Partial purification and alkylation of HPV-18 E6. E. coli AR120 cells containing pAS-18 E6 were induced as described above. Cells were then collected, extracted three times with 70~ formic acid and washed consecutively with 10 mM-Tris-HCl pH 8.8 and 10 mM-Tris-HC1 pH 7.5. The pellet was then resuspended in 0.5~ SDS, 25 mMdithiothreitol (DTT) and boiled for 3 rain. After centrifugation, the supernatant was lyophilized, resuspended in 0.1 M-Tris HC1 pH 7.5, 0.5~ SDS, 10 mM-2-mercaptoethanol and the proteins were separated by Superose 12 fast protein liquid chromatography (FPLC; Pharmacia). Peak fractions containing E6 were pooled, and dialysed in 10% glycerol, 0-02~o SDS, 2 mM-2-mercaptoethanol and 10 mM-Tris-HC1 pH 7.5. Alkylation was done as described previously (Crawford & O'Farrell, 1979) . Briefly, 10 gl of column-fractionated E6 was added to 20 gl 1 ~ SDS, 20 mM-DTT and heated at 100°C for 3 min, rapidly cooled, and exposed to Nethylmaleimide (NEM) for 1 h at 0°C. The NEM was prepared freshly at 0.2 M and 10 gl was added to each sample. The reaction was stopped by addition of 10 ~tl 50~ glycerol, 0.5 M-2-mercaptoethanol.
Immunoprecipitation. Immunoprecipitation of HPV protein from human cells was done as described by Androphy et al (1987) . Briefly, 1 x 106 cells were labelled with 1 mCi [35S]cysteine for 3 h. Cells were then washed with phosphate-buffered saline containing 1 ~ aprotinin (Boehringer Mannheim) and suspended in STE buffer (20 mM-Tris-HC1 pH 7.2, 140 mM-NaCI, 1 mM-EDTA, 1 ~ aprotinin). The cells were pelleted and lysed in 200 gl of RIPA buffer without SDS (50mM Tris-HC1 pH 7-4, 150mM-NaC1, 1 mM-EDTA, 1~ Triton X-100, 1~ deoxycholic acid) plus 0-5 ~ SDS. After vortexing thoroughly, 800 gl of RIPA buffer without SDS was added, and the cell lysate was passed several times through a syringe and needle. The cell lysate was then incubated with 500 p.! of 20~ Protein A Sepharose (Pharmacia) at 4°C for 20 min, after which the supernatant was removed and incubated with appropriate antibody for 45 rain at 4°C. Seventy-five gl of 20~ Protein A-Sepharose was then added and allowed to react for 40 min at 4°C. The Protein A Sepharose was then pelleted, washed three times with RIPA buffer, three times with RIPA high salt buffer (20 mM-Tris-HC1 pH 7.4, 1 M-NaC1, 1 ~ Nonidet P40, 0-1 SDS) and finally three times with RIPA buffer again. The pellet was then suspended in sample buffer (3~ SDS, 1.6 M-urea, 33 mM-2-mercaptoethanol) and boiled for 2 rain. The Protein A-Sepharose was then pelleted and the supernatant was removed and analysed by SDS-PAGE and fluorography. 14-3 tested by ELISA for anti-E6 antibody using HPV-18 E6 protein which had been synthesized in E. coli AR120 containing the pAS-18 E6 plasmid. Polyclonal cells shown to be producing antibody against HPV-18 E6 were then cloned by limiting dilution. From three separate cell fusions a total of seven independently derived antibody-producing clones were obtained.
RESULTS

Production of monoclonal antibodies to HPV-18 E6-13-galactosidase fusion protein
To analyse the specificity of these antibodies immunoblotting was done on HPV-18 E6 derived from the pAS-18 E6 plasmid. The results obtained are shown in Fig. 1 ; (a) to (e) show the reactions of five different monoclonal antibodies with extracts of E. coli AR120 which were either uninduced (lane 1) or induced (lane 2) with nalidixic acid; (10 shows the reaction of a preimmune antiserum and (g) shows a Coomassie Brilliant Blue stain of total proteins from uninduced and induced cultures. Clearly the five antibodies shown here, D2A6, B1A2, C1P5, B 1 B 3 and C 1X 1, react specifically with HPV-18 E6 synthesized in bacteria. Similar patterns of reactivity were observed with the two remaining monoclonal antibodies (data not shown). It is also noticeable from this result that all the monoclonal antibodies reacted with a higher mol. wt. protein of approximately 31K. The presence of this band was specific for cells synthesizing E6 polypeptide, and therefore did not appear to represent a non-specific reaction. Also crossblocking studies (data not shown) indicated that these antibodies recognized at least four different epitopes on HPV-18 E6 and all of them reacted with the 31K protein. From its size the 31K protein might be a dimer of the 15.8K HPV-18 E6 protein. Alternatively it might have resulted from a rearrangement of the plasmid such that some E6 sequence became attached to a plasmid-derived sequence to generate a chimeric protein.
To investigate this possibility further, E. coli AR120 cells containing pAS-18 E6 were grown in the presence of nalidixic acid, the cells were extracted with formic acid, and proteins were separated by size in FPLC. The extracts were then reacted with various concentrations of reducing agent. The effect of alkylation was also investigated since this should block formation of disulphide bonds. The extracts were then subjected to immunoblot analysis with C1P5 antibody; the results obtained are shown in Fig. 2 . Lane 1 shows the reaction obtained after alkylation with NEM, and clearly the E6 protein migrated somewhat more slowly, with an apparent mol. wt. of 16.5 K. In addition the 31K protein disappeared completely. Lanes 2 and 3 show the reaction obtained after boiling the protein extracts in either 3~ SDS, 1.6 M-urea, 33 mM-2-mercaptoethanol or 3 ~ SDS, 1.6 M-urea respectively. In the absence of reducing agent, the amount of monomeric E6 decreased with a concomitant increase in the 31K protein. These results suggest that in E. coli, HPV-18 E6 protein can exist as a dimer through the formation of disulphide bridges between the cysteine residues of different molecules.
Immunological analysis of H P V E6 proteins
From sequence data (Seedorf et al., 1985; Matlashewski et al., 1986a) there is approximately 6 0~ homology between the putative E6 amino acid sequences of HPV-16 and HPV-18. In addition, all papillomavirus E 6 0 R F s so far analysed exhibit a fourfold repetition with similar spacing for the tetrapeptide sequence Cys-X-X-Cys. These data indicate that the E6 proteins a r e quite highly conserved between different HPV types. Hence we decided to investigate the degree of immunological conservation between the E6 proteins of HPV-16 and HPV-18.
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14.3 Prior to attempting this analysis it was necessary to be able to synthesize HPV-16 E6 protein by itself. As for HPV-18 E6 (Matlashewski et al., 1986a) , the pAS-1 vector was used. A 551 bp fragment containing the whole of HPV-16 E6 was obtained by Bal31 exonuclease digestion, and this was cloned into pAS-1 as described in Methods (Fig. 3a) . The resulting plasmid (pAS-16E6) was transfected into E. coli AR120, induced with nalidixic acid and the proteins were analysed by SDS-PAGE (Fig. 3b) . A protein of about 17K mol. wt. was present in cells treated with nalidixic acid (Fig. 3, lane 2) but not in untreated cells (Fig. 3, lane 1) . This corresponds very closely to the size of HPV-16 E6 predicted from the DNA sequence.
As a final check that pAS-16E6-derived protein was translated correctly in E. coli this protein was analysed by an HPV-16 E6 peptide antiserum. The antiserum was raised against a peptide comprising the first 14 N-terminal amino acids of HPV-16 E6 as described previously (Matlashewski et al., 1986 a) . The results obtained are shown in Fig. 4 (0. Clearly the HPV-16 E6 peptide antiserum reacts strongly with the 17K mol. wt. protein induced in cells treated with nalidixic acid. This demonstrates that the HPV-16 E 6 0 R F identified is used by these bacteria to make HPV-16 E6 protein.
For immunological analysis of the HPV E6 proteins, E. coli AR120 containing pAS-18 E6 and pAS-16 E6 were induced with nalidixic acid and the proteins produced were analysed by immunoblotting with the collection of E6 monoclonal antibodies. The results obtained are shown in Fig. 4; (a) shows the Coomassie Brilliant Blue stain of cell extracts used for the immunoblotting and clearly there was a significant difference in mol. wt. between the HPV-16 E6 (lane 1) and HPV-18 E6 (lane 2) proteins. This was due to the presence of 19 additional amino acids in the HPV-16 E6 protein product. A number of points are evident from the immunoblotting data. First, the monoclonal antibodies D2A6, C1N 1, C1X1, B 1B3 and B 1 A2 (Fig. 4 b to f ) reacted only with HPV-18 E6, indicating that these antibodies recognized HPV-18-specific epitopes on the E6 polypeptide. Second, antibody C1P5 (Fig. 4g ) reacted with E6 protein from both HPV-16 and HPV-18, indicating that this antibody recognized a conserved epitope on the E6 protein. This is of interest when compared with the reaction of the HPV-18 E6 polyclonal antibody (Fig. 4h ) which reacted only with the HPV-18 E6, showing virtually no cross-reactivity between the two proteins. Hence it appears that the majority of antigenic determinants on the E6 protein are not conserved between HPV types. Finally, the peptide antibodies to HPV-16 and HPV-18 E6 (Fig. 4i and j respectively) showed no cross-reactivity with heterologous protein, demonstrating no antigenic conservation in the N-terminal region of the E6 protein, as would be predicted from the DNA sequence. Higher mol. wt. proteins are also seen in Fig. 4 (e) , (f) and (g). These may correspond to the 31K protein noted in Fig. 1 . 4) ; anti-HPV-16 E6 polyclonal antibody (lane 5); mouse preimmune sera (lanes 3 and 6). Immunoprecipitated HPV E6 proteins are indicated by the arrows. (b) As for (a) using HeLa cell extract. Monoclonal antibodies BIA2, B1FI, C1P5, C1N1 and C1X1 were used here (lanes 1 to 5 respectively) followed in each case by rabbit anti-mouse immunoglobulin serum. Polyclonal anti-HPV-18 E6 antibody (lane 6) and control mouse serum (lane 7) were included for comparison.
Analysis of E6 protein expression in human cells
A number of cell lines derived from human cervical carcinomas containing HPV-16 and HPV-18 DNAs are available. Hence we proceeded to analyse some of these cell lines for HPV E6 expression. For these analyses immunoprecipitations were done following the procedure devised by Androphy et al. (1987) as described in Methods. The results obtained using polyclonal antiserum raised against the HPV-18 E6-/~-galactosidase fusion protein are shown in Fig. 5 (a) . Clearly this antiserum precipitated a 16.5K mol. wt. protein from the HPV-18 D N Acontaining HeLa cells (lane 2) but not from the HPV DNA-negative C33-I cells (lane 4). In addition, if the HPV-18 E6 /3-galactosidase antiserum was incubated with FPLC-purified HPV-18 E6 protein prior to immunoprecipitation, no 16.5K mol. wt. protein was observed (lane 1). This result clearly demonstrates that the HPV-18 E6 polypeptide was being expressed in HeLa cells. In addition, comparison with the HPV-16 DNA-containing SiHa cells reacted with an antibody raised against a HPV-16 E6 2-Cn fusion protein (Androphy et al., 1987) (lane 5) indicates that the HPV-18 E6 protein had a slightly lower tool. wt. than the HPV-16 E6 protein, as would be expected from their respective DNA sequences (Seedorf et al., 1985; Matlashewski et al., 1986a) .
The anti-E6 monoclonal antibodies were also active in immunoprecipitating HPV-18 E6 from HeLa cell extracts (Fig. 5b) . As they are mostly of the IgG1 subclass a second antibody was included here. C1X1 and C1P5 were the most effective antibodies in immunoprecipitation, precipitating almost as much E6 as the polyclonal antiserum.
DISCUSSION
Identification of the HPV E6 polypeptide in ceils derived from human cervical carcinomas is a major step in elucidating the role of this putative transforming protein in cervical carcinoma. Since the gene coding for BPV E6 has been shown to be involved in BPV cell transformation (Schiller et al., 1984; Yang et al., 1985; Androphy eta/., 1985) , it is particularly significant that the equivalent HPV protein has been identified in a cell line derived from a human tumour. The reagents described in this paper now enable us to look at HPV E6 expression in a variety of systems.
In addition to allowing the detection of HPV-18 E6 in human cells, the antibodies described also reveal a number of interesting features about the E6 polypeptides synthesized in bacteria. From nucleotide sequence data there appears to be a considerable degree of conservation in E6 between different HPV types. This panel of antibodies however clearly show that E6 is not immunologically conserved between HPV-16 and HPV-18. Both the polyclonal antisera and the majority of the monoclonal antibodies react only with the homologous protein. One monoclonal antibody, CIP5, does however cross-react with HPV-16 and HPV-18 E6, demonstrating conservation of at least one epitope on the E6 polypeptide. It remains to be seen whether this represents a conserved region of the protein which is functionally important. Neither the HPV-16 nor HPV-18 E6 polyclonal antibodies reacted against E6 from the heterologous virus.
The results obtained from alkylation of HPV-18 E6 are also particularly interesting. In the presence of NEM, HPV-18 E6 synthesized in E. coli migrates at 16.5K as opposed to 15.8K normally. In addition, the 31K protein is present in much smaller amounts. Immunoblots done on HPV-18 E6 without reducing agent however, show a quantitative increase in the 31K protein and an equivalent reduction in the E6 15.8K protein. From the sizes of the 15.8K and 31K proteins it thus seems likely that E6 can form a dimer in E. coli. In addition, when higher titre antibody was used against HPV-16 E6 an additional protein of 35K mol. wt. was seen, indicating that HPV-16 E6 in bacterial extracts can form a dimer. Presumably this occurs through the formation of disulphide bonds between at least two of the many cysteine residues present in the E6 polypeptide and alkylation thus blocks the formation of these bonds. The response of E6 to alkylation is also very similar to that observed for simian virus 40 (SV40) small t antigen (Crawford & O'Farrell, 1979) . In addition, the Cys-X-X-Cys sequence homology observed in the E6 proteins of papiUomaviruses is also present in SV40 small t antigen (Fiers et al., 1978) . It remains to be seen whether any other similarities exist between the HPV E6 protein and the SV40 small t antigen.
Identification of the HPV E6 protein follows identification of the HPV-16 E7 protein in cells derived from human cervical carcinomas (Smotkin & Wettstein, 1986 ) and HPV-la E4 protein in papillomas (Doorbar et al., 1986) . The continued expression of both E6 and E7 proteins in these cell lines suggests that both proteins may be required for maintenance of the transformed phenotype. Clearly, HPV E6 is only expressed at very low levels and requires particularly rigorous extraction procedures, both of which observations indicate that analyses of E6 expression in human biopsy material will be difficult. Analysis of HPV-18 E6-related eDNA clones, derived from HeLa cell messenger RNA, has indicated that most of the RNA from this region of the HPV genome codes from a truncated E6 polypeptide, E6*, rather than for full length E6 (Schneider-Gadicke & Schwarz, 1986) . However, we have been unable to detect a polypeptide with the properties predicted for E6*, either because our antibodies failed to react with it or because it is present in amounts too small to be detected in our immunoprecipitation assays. However, the antibodies described here will be particularly useful for analysing E6 protein expression in cell transformation studies which are currently in progress (Matlashewski et al., 1986b) .
